Adjuvant TACE combined with tislelizumab in patients with resected hepatocellular carcinoma at high risk of recurrence: An open-label, multicenter, phase II trial

被引：0
|
作者：
Ma, T. [1 ]
Wen, L. [1 ]
Zhang, J. [2 ]
Zhang, Z. [3 ]
Zeng, Y. [4 ]
Wang, Y. [5 ]
Zheng, J. [6 ]
Liang, T. [1 ]
机构：
[1] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hepatobiliary & Pancreat Surg, Hangzhou, Peoples R China
[2] China Med Univ, Affiliated Hosp 1, Clin Med, Shenyang, Peoples R China
[3] Shandong Univ, Qilu Hosp, Dept Hepatobiliary Surg, Jinan, Peoples R China
[4] Fujian Med Univ, Mengchao Hepatobiliary Hosp, Dept Hepatobiliary & Pancreat Surg, Fuzhou, Peoples R China
[5] Tianjin Third Cent Hosp, Dept Hepatobiliary Surg, Tianjin, Peoples R China
[6] Hainan Gen Hosp, Dept Hepatobiliary & Pancreat Surg, Haikou, Hainan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.259
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
239P
引用
收藏
页码：S1494 / S1494
页数：1
相关论文
共 50 条
  • [21] A multicenter, phase Ib/II, open-label study of tivozanib with durvalumab in advanced hepatocellular carcinoma (DEDUCTIVE)
    Mahmood, Sharmeen
    Li, Daneng
    Lee, Arielle
    Rowe, Julie
    Beg, Muhammed
    Kasturi, Vijay
    Iyer, Renuka
    Abrams, Thomas
    Dayyani, Farshid
    FUTURE ONCOLOGY, 2022, 18 (40) : 4465 - 4471
  • [22] Efficacy and safety of Huachansu combined with adjuvant chemotherapy in resected colorectal cancer patients: a prospective, open-label, randomized phase II study
    Li, Shichao
    Shen, Dongxiao
    Zuo, Qingsong
    Wang, Shengzi
    Meng, Lingjia
    Yu, Jiaojiao
    Liu, Yang
    Li, Wusheng
    Chen, Chao
    Yin, Peihao
    Chen, Teng
    Wang, Jie
    MEDICAL ONCOLOGY, 2023, 40 (12)
  • [23] A phase 2, multicenter study to evaluate the efficacy and safety of TACE sequential tislelizumab as adjuvant therapy in patients with HCC at high risk of recurrence after curative resection
    Liang, Tingbo
    Zhang, Zongli
    Zheng, Jinfang
    Wang, Yijun
    Zhang, Jialin
    Li, Bo
    Ma, Tao
    Xu, Yunfei
    Wu, Changxiong
    Sun, Quan
    Meng, Yiman
    Yang, Xiaoli
    CANCER RESEARCH, 2022, 82 (12)
  • [24] Adjuvant transarterial chemoembolization for hepatocellular carcinoma following curative resection: A randomized, open-label, phase 3 trial
    Ma, Tao
    Bai, Xueli
    Zhang, Qi
    Chen, Wen
    Huang, Kaiquan
    Qian, Tao
    Xu, Yongzi
    Sun, Peiwei
    Chen, Yiwen
    Xiao, Wenbo
    Sun, Ke
    Gao, Shunliang
    Liang, Tingbo
    HEPATOLOGY, 2025,
  • [25] Efficacy and safety of envafolimab plus lenvatinib combined with TACE in initially unresectable hepatocellular carcinoma: An open-label, single-arm, phase II study
    Bai, Xueli
    Chen, Yiwen
    Zhang, Junlei
    Hu, Wendi
    Li, Xiang
    Shen, Yan
    Zhang, Min
    Wu, Jian
    Gao, Shunliang
    Yu, Jun
    Que, Risheng
    Zhang, Yun
    Yang, Fuchun
    Xia, Weiliang
    Zhang, Aibin
    Tang, Xiaofeng
    Liang, Tingbo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial
    Geissler, Edward K.
    Schnitzbauer, Andreas A.
    Zuelke, Carl
    Lamby, Philipp E.
    Proneth, Andrea
    Duvoux, Christophe
    Burra, Patrizia
    Jauch, Karl-Walter
    Rentsch, Markus
    Ganten, Tom M.
    Schmidt, Jan
    Settmacher, Utz
    Heise, Michael
    Rossi, Giorgio
    Cillo, Umberto
    Kneteman, Norman
    Adam, Rene
    van Hoek, Bart
    Bachellier, Philippe
    Wolf, Philippe
    Rostaing, Lionel
    Bechstein, Wolf O.
    Rizell, Magnus
    Powell, James
    Hidalgo, Ernest
    Gugenheim, Jean
    Wolters, Heiner
    Brockmann, Jens
    Roy, Andre
    Mutzbauer, Ingrid
    Schlitt, Angela
    Beckebaum, Susanne
    Graeb, Christian
    Nadalin, Silvio
    Valente, Umberto
    Sanchez Turrion, Victor
    Jamieson, Neville
    Scholz, Tim
    Colledan, Michele
    Faendrich, Fred
    Becker, Thomas
    Soderdahl, Gunnar
    Chazouilleres, Olivier
    Makisalo, Heikki
    Pageaux, Georges-Philippe
    Steininger, Rudolf
    Soliman, Thomas
    de Jong, Koert P.
    Pirenne, Jacques
    Margreiter, Raimund
    TRANSPLANTATION, 2016, 100 (01) : 116 - 125
  • [27] Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
    Wang, Kang
    Xiang, Yan-Jun
    Yu, Hong-Ming
    Cheng, Yu-Qiang
    Liu, Zong-Han
    Qin, Ying-Yi
    Shi, Jie
    Guo, Wei-Xing
    Lu, Chong-De
    Zheng, Ya-Xin
    Zhou, Fei-Guo
    Yan, Mao-Lin
    Zhou, Hong-Kun
    Liang, Chao
    Zhang, Fan
    Wei, Wen-Jing
    Lau, Wan Yee
    Li, Jing-Jing
    Liu, Yan-Fang
    Cheng, Shu-Qun
    NATURE MEDICINE, 2024, 30 (03) : 708 - +
  • [28] Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
    Kang Wang
    Yan-Jun Xiang
    Hong-Ming Yu
    Yu-Qiang Cheng
    Zong-Han Liu
    Ying-Yi Qin
    Jie Shi
    Wei-Xing Guo
    Chong-De Lu
    Ya-Xin Zheng
    Fei-Guo Zhou
    Mao-Lin Yan
    Hong-Kun Zhou
    Chao Liang
    Fan Zhang
    Wen-Jing Wei
    Wan Yee Lau
    Jing-Jing Li
    Yan-Fang Liu
    Shu-Qun Cheng
    Nature Medicine, 2024, 30 : 708 - 715
  • [29] Update results from ALTER-H004 study: Anlotinib combined with TACE as adjuvant therapy in hepatocellular carcinoma patients at high risk of recurrence after surgery-A single-arm, multicenter, phase II clinical trial.
    Wu, Zheng
    Wang, Zheng
    Zhang, Lei
    Song, Xiaojing
    Du, Xilin
    Tan, Kai
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16120 - E16120
  • [30] Phase II study of adjuvant tislelizumab combined with interferon-a and active surveillance in hepatocellular carcinoma patients with microvascular invasion
    Wang, Y.
    Wu, Y.
    Xu, W.
    Zhao, Y.
    Zhu, W.
    Zhang, T.
    Wang, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S598 - S598
12345